Effect of Efpeglenatide on Cardiovascular Outcomes

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk. Secondary Objectives: To demonstrate that efpeglenatide 4 and 6 mg was superior to placebo in T2DM participants with high CV risk on the following parameters: * 3-point MACE. * Expanded CV outcome. * Composite outcome of new or worsening nephropathy. To assess the safety and tolerability of efpeglenatide 4 and 6 mg, both added to standard of care in T2DM participants at high CV risk.

Key facts

Study ID

NCT03496298

Run by

Sanofi

People needed

4076

Starts

2018-04-27

Expected to finish

2020-12-10

Last updated by the study team

2021-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• T2DM with glycosylated hemoglobin (HbA1c) greater than (>) 7 percentage.
• Age 18 years or older who met at least one of the cardiovascular disease criteria or age 50 years (male), 55 years (female) or older with glomerular filtration rate greater than or equal to 25 and less than 60 milliliters per minute and at least had one cardiovascular risk factor.
• Female participants agreed to follow contraceptive guidance.
• Signed written informed consent.

You may not qualify if…

• Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting.
• History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of any type of acute pancreatitis within 3 months prior to screening.
• Personal or family history of medullary thyroid cancer.
• Hypertension (with a systolic blood pressure >180 millimeters of Mercury [mmHg] and/or diastolic blood pressure >100 mmHg).
• Hospitalization for hypertensive emergency within 3 months prior to randomization.
• Planned coronary procedure or surgery after randomization.
• No documented ophthalmologic exam with fundoscopy within 6 months prior to randomization.
• Retinopathy or maculopathy with treatment, either recent (3 months prior to randomization) or planned during the study.
• Treated with any glucagon-like peptide-1 receptor agonist product alone (eg, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or in combination within 3 months prior to screening.
• Use of any Dipeptidyl peptidase 4 inhibitor within 3 months prior to screening.
• Antihyperglycemic treatment had not been stable within 3 months prior to screening.
• The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 8400014 — Gilbert, Arizona, United States
• Investigational Site Number 8400012 — Surprise, Arizona, United States
• Investigational Site Number 8400046 — Tucson, Arizona, United States
• Investigational Site Number 8400022 — Beverly Hills, California, United States
• Investigational Site Number 8400065 — Concord, California, United States
• Investigational Site Number 8400060 — Greenbrae, California, United States
• Investigational Site Number 8400084 — Long Beach, California, United States
• Investigational Site Number 8400002 — Los Gatos, California, United States
• Investigational Site Number 8400085 — Northridge, California, United States
• Investigational Site Number 8400082 — Pomona, California, United States
• Investigational Site Number 8400025 — Sacramento, California, United States
• Investigational Site Number 8400064 — Englewood, Colorado, United States
• Investigational Site Number 8400019 — Hamden, Connecticut, United States
• Investigational Site Number 8400023 — Waterbury, Connecticut, United States
• Investigational Site Number 8400091 — Hialeah, Florida, United States
• Investigational Site Number 8400040 — Hollywood, Florida, United States
• Investigational Site Number 8400073 — Hudson, Florida, United States
• Investigational Site Number 8400011 — Jacksonville, Florida, United States
• Investigational Site Number 8400017 — Jacksonville, Florida, United States
• Investigational Site Number 8400042 — Jacksonville, Florida, United States
• Investigational Site Number 8400027 — Miami, Florida, United States
• Investigational Site Number 8400051 — Miami, Florida, United States
• Investigational Site Number 8400041 — New Port Richey, Florida, United States
• Investigational Site Number 8400059 — Ormond Beach, Florida, United States
• Investigational Site Number 8400032 — Sheffield, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.